As market access decisions grow more complex, pharmaceutical organizations need a more connected evidence strategy. In this webinar, Jessica Lovett, Alison Oliver, and Belinda Yap explore how real-world evidence (RWE), patient support program (PSP) data, and artificial intelligence (AI) are converging into an integrated evidence ecosystem that can support payer engagement, health technology assessment (HTA) submissions, and access planning.

As stakeholders look for new ways to support access and reimbursement decisions in Canada, organizations are increasingly connecting patient support, real-world data, and advanced analytics. PSPs are evolving into important sources of longitudinal real-world data, while AI is helping teams analyze and apply evidence at scale. Together, these capabilities can support more informed access decisions.

This session is designed for pharmaceutical leaders across market access, medical affairs, evidence generation, patient support, and commercial teams who are looking to maximize data into a more integrated evidence strategy.